• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization

byJessie WillisandTeddy Guo
December 15, 2021
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against admission to hospital due to COVID-19 infection.

2. A third dose was also associated less severe disease and lower COVID-19 related mortality.

Evidence Rating Level: 2 (Good)

Study Rundown: Despite a rigorous vaccination campaign in Israel, the country is still reporting vaccine “breakthrough” cases of COVID-19. Israel, which has already rolled out many third doses of BNT162b2 mRNA vaccine, may be used as a pseudo-trial population to evaluate third dose vaccine effectiveness. This was the goal of this study, which compared individuals who had received a third dose at least 5 months after their second dose. Using demographically matched controls with only two doses, effectiveness of preventing hospitalization, severe disease and death was measured. This study found that a third dose of the BNT162b2 was highly effective at preventing hospitalization compared to two doses. Three doses were also more effective at preventing severe disease and death from COVID-19. Efficacy from a third dose was most pronounced in individuals over the age of 40. Limitations included lack of individual data for patients under 40. Nonetheless, this study provides key information which will help inform national vaccination strategies moving forward.

Click to read the study in the Lancet

Click to read an accompanying editorial in the Lancet

Relevant Reading: Vaccine breakthrough infections: the possibility of getting COVID-19 after getting vaccinated

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

2 Minute Medicine Rewind January 23, 2023

Unvaccinated status increases risk of long COVID symptoms

In-Depth [retrospective cohort]: This retrospective study utilized the large number of vaccinated Israeli population to investigate the effectiveness of a third dose of the mRNA BNT162b2 (Pfizer) vaccine. The eligible population included individuals who had received two doses at least 5 months prior to their third dose. A matched control group was also included which exactly matched the treatment group by age, sex, place of residence, and risk factors for severe COVID-19 infection, but had only received two doses total. There were 728 321 matched pairs, 51% female and a median age of 52 years. 198 476 individuals were matched to themselves before and after third dose. Outcomes included risk of admission to hospital, severe disease, and death from COVID-19 infection. Outcomes were recorded 7 days after third dosage was received and continued for a median follow-up of 13 days.

Compared to two doses, a third dose conferred an effectiveness of 93% against hospital admission, 92% against severe disease and 81% against death from COVID-19. Similar effectiveness difference was seen in comparing males and females. For age group, greater significance in effectiveness difference was seen in age groups 40-69 (92%) and >70 (93%), than compared to ages 16-39 (70%).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #Pfizer-BioNTechbnt162b2COVID-19mRNA vaccineSARS-CoV-2vaccine
Previous Post

The risk of dementia is associated with being greater at the extremes of systolic blood pressure in adults 75 or older

Next Post

Direct comparison of neoadjuvant and adjuvant chemotherapy and radiotherapy for survival outcomes from resectable gastric cancer

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Next Post
Equivalent efficacy of Paclitaxel or Irinotecan for advanced gastric cancer

Direct comparison of neoadjuvant and adjuvant chemotherapy and radiotherapy for survival outcomes from resectable gastric cancer

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

Adolescents’ muscle strength associated with lower cardiometabolic risk

Wellness Check: Exercise

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options